Cutaneous Melanoma-A Review in Detection, Staging, and Management.

[1]  S. Leachman,et al.  Identification of patients at risk of metastasis using a prognostic 31‐gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria , 2019, Journal of the American Academy of Dermatology.

[2]  R. Hofmann-Wellenhof,et al.  Dermoscopy vs. reflectance confocal microscopy for the diagnosis of lentigo maligna , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  R. Scolyer,et al.  Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond , 2018, Annals of Surgical Oncology.

[4]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[5]  A. Khorana,et al.  Determination of the impact of melanoma surgical timing on survival using the National Cancer Database , 2018, Journal of the American Academy of Dermatology.

[6]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[7]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[8]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[9]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[10]  D. Lambrechts,et al.  Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial , 2017, BMC Cancer.

[11]  A. Gesierich,et al.  Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[12]  L. Billingham,et al.  Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT‐1 study , 2017, The British journal of dermatology.

[13]  F. Hodi,et al.  Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma , 2016, Oncotarget.

[14]  R. Dellavalle,et al.  Primary and Secondary Chemoprevention of Malignant Melanoma , 2016, American Journal of Clinical Dermatology.

[15]  Tumaini R. Coker,et al.  Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. , 2023, JAMA.

[16]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[17]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[18]  Greta M. Massetti,et al.  Vital Signs: Melanoma Incidence and Mortality Trends and Projections — United States, 1982–2030 , 2015, MMWR. Morbidity and mortality weekly report.

[19]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[20]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[21]  K. Delman,et al.  The emerging role of radiotherapy for desmoplastic melanoma and implications for future research , 2015, Melanoma research.

[22]  P. Baade,et al.  More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. , 2015, The Journal of investigative dermatology.

[23]  D. Elder.  Pathology of melanoma. , 2015, Surgical oncology clinics of North America.

[24]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[26]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[27]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[28]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[29]  I. Stanganelli,et al.  Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. , 2014, European journal of cancer.

[30]  J. Elmore,et al.  The MPATH-Dx reporting schema for melanocytic proliferations and melanoma. , 2014, Journal of the American Academy of Dermatology.

[31]  L. Layfield,et al.  Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis. , 2013, American journal of clinical pathology.

[32]  I. Orengo,et al.  The rate of melanoma transection with various biopsy techniques and the influence of tumor transection on patient survival. , 2013, Journal of the American Academy of Dermatology.

[33]  Peter Boyle,et al.  Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[34]  L. Mallbris,et al.  Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. , 2012, Journal of the American Academy of Dermatology.

[35]  Andrea B Herschorn.  Dermoscopy for melanoma detection in family practice. , 2012, Canadian family physician Medecin de famille canadien.

[36]  Sandra Nolte,et al.  Systematic skin cancer screening in Northern Germany. , 2012, Journal of the American Academy of Dermatology.

[37]  C. Tzen,et al.  Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma , 2011, Pigment cell & melanoma research.

[38]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[39]  J. Barrett,et al.  Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK , 2011, Journal of Medical Genetics.

[40]  Gail M Williams,et al.  Reduced melanoma after regular sunscreen use: randomized trial follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Amanda Oakley,et al.  Digital monitoring by whole body photography and sequential digital dermoscopy detects thinner melanomas. , 2010, Journal of primary health care.

[42]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[43]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[44]  D. Elder,et al.  Melanocytic Tumors of Uncertain Malignant Potential: Results of a Tutorial Held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008 , 2010, The American journal of surgical pathology.

[45]  D. English,et al.  Clinical whole‐body skin examination reduces the incidence of thick melanomas , 2009, International journal of cancer.

[46]  A. Debucquoy,et al.  Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  Kurt Straif,et al.  A review of human carcinogens--part D: radiation. , 2009, The Lancet. Oncology.

[48]  A. Hauschild,et al.  Surgery and radiotherapy in the treatment of cutaneous melanoma , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  J. Gershenwald,et al.  Role of sentinel lymph node biopsy in patients with thin melanoma. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[50]  Susan Muller,et al.  KIT Gene Mutations and Copy Number in Melanoma Subtypes , 2008, Clinical Cancer Research.

[51]  S. Menzies,et al.  Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta‐analysis of studies performed in a clinical setting , 2008, The British journal of dermatology.

[52]  R. Elashoff,et al.  Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.

[53]  A. Bleyer,et al.  Cancer in 15- to 29-year-olds by primary site. , 2006, The oncologist.

[54]  H. Sasano.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[55]  M. Helfand,et al.  Screening for skin cancer. , 2001, American journal of preventive medicine.

[56]  L. Karnell,et al.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.